Ensign Peak Advisors
QNCX icon

Ensign Peak Advisors’s Quince Therapeutics QNCX Stock Holding History

Ensign Peak Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-165
Closed -$205K – 2197
2022
Q1 		$205K Hold
165
– – ﹤0.01% 1872
2021
Q4 		$417K Buy
+165
New +$1.01M ﹤0.01% 1687

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Ensign Peak Advisors's QNCX Position: Q2 2022 in Review

Ensign Peak Advisors sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 165 shares — an estimated $205K sold.

Ensign Peak Advisors first reported a position in QNCX in Q4 2021 and held it in 2 quarters. The position peaked at $417K in Q4 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • Ensign Peak Advisors reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 165 Quince Therapeutics shares in Q2 2022, an estimated $205K.
  • Ensign Peak Advisors first reported a position in Quince Therapeutics in Q4 2021 and held it in 2 quarters.
  • Ensign Peak Advisors's Quince Therapeutics position peaked at $417K in Q4 2021.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.